# Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

> **NCT07682129** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Entrada Therapeutics, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy (DMD)

## Interventions

- **DRUG:** ENTR-601-44
- **DRUG:** ENTR-601-45

## Key facts

- **NCT ID:** NCT07682129
- **Lead sponsor:** Entrada Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2032-03
- **Final completion:** 2032-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682129, "Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07682129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*